Acumen Pharmaceuticals, Inc. ABOS
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances)
Chart by TradingView
1/9
Piotroski F — financial health
-12.29
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$121.3M | — | — | $70.4M |
| 2024 | — | -$102.3M | — | — | $181.8M |
| 2023 | — | -$52.4M | — | — | $267.0M |
| 2022 | — | -$42.9M | — | — | $188.8M |
| 2021 | — | -$100.6M | — | — | $225.2M |
| 2020 | — | -$7.3M | — | — | -$18.6M |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -12.29 (distress)
- Working capital / assets 0.751
- Retained earnings / assets -3.635
- EBIT / assets -1.008
- Equity / liabilities 1.344
Source: SEC EDGAR filings · CIK 0001576885 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.